Last reviewed · How we verify
Metformin Eicosapentaenoate — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Metformin Eicosapentaenoate (Metformin Eicosapentaenoate) — Thetis Pharmaceuticals LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Metformin Eicosapentaenoate TARGET | Metformin Eicosapentaenoate | Thetis Pharmaceuticals LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Metformin Eicosapentaenoate CI watch — RSS
- Metformin Eicosapentaenoate CI watch — Atom
- Metformin Eicosapentaenoate CI watch — JSON
- Metformin Eicosapentaenoate alone — RSS
Cite this brief
Drug Landscape (2026). Metformin Eicosapentaenoate — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-eicosapentaenoate. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing